Skip to content

Processa Pharmaceuticals, Inc.: 10-Q filed 2022-08-11

What Processa Pharmaceuticals, Inc. reported in its quarterly report filed 2022-08-11 (fiscal Q2 2022): 32 published measures, 79 facts as tagged in accession 0001493152-22-022063.

This filing

Form
10-Q (quarterly report)
Filed
2022-08-11
Fiscal period
fiscal Q2 2022
Accession
0001493152-22-022063 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Processa Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-06-3021,657,590USD
At 2021-12-3126,463,505USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2022-06-301,575,723USD
At 2021-12-31978,405USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-06-3020,081,867USD
At 2022-03-3123,236,866USD
At 2021-12-3125,485,100USD
At 2021-06-3029,241,692USD
At 2021-03-3131,336,139USD
At 2020-12-3122,939,478USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2022-06-3012,064,142USD
At 2021-12-3116,497,581USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-5,164,368USD91
2022-01-01 to 2022-06-30-8,391,499USD181
2022-01-01 to 2022-03-31-3,227,131USD90
2021-04-01 to 2021-06-30-3,157,043USD91
2021-01-01 to 2021-06-30-5,256,523USD181
2021-01-01 to 2021-03-31-2,099,480USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-01-01 to 2022-06-30-4,133,439USD181
2021-01-01 to 2021-06-30-4,437,494USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2022-01-01 to 2022-06-300USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-01-01 to 2022-06-30-300,000USD181
2021-01-01 to 2021-06-309,852,465USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-06-30-45,214,831USD
At 2021-12-31-36,823,332USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2022-04-01 to 2022-06-3015,940,510shares91
2022-01-01 to 2022-06-3015,886,116shares181
2021-04-01 to 2021-06-3015,406,363shares91
2021-01-01 to 2021-06-3014,997,303shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-0.32USD/shares91
2022-01-01 to 2022-06-30-0.53USD/shares181
2021-04-01 to 2021-06-30-0.2USD/shares91
2021-01-01 to 2021-06-30-0.35USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2021-04-01 to 2021-06-30-137,169USD91
2021-01-01 to 2021-06-30-226,417USD181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-04-01 to 2022-06-302,009,369USD91
2022-01-01 to 2022-06-302,838,266USD181
2021-04-01 to 2021-06-30865,323USD91
2021-01-01 to 2021-06-301,173,622USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-5,171,748USD91
2022-01-01 to 2022-06-30-8,400,462USD181
2021-04-01 to 2021-06-30-3,459,797USD91
2021-01-01 to 2021-06-30-5,653,104USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2022-06-3013,960,775USD
At 2021-12-3118,327,151USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2021-01-01 to 2021-06-30362USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2022-06-301,571,068USD
At 2021-12-31971,020USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2022-06-30648,104USD
At 2021-12-31218,905USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2022-06-307,662,390USD
At 2021-12-318,056,638USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-06-3015,819,317shares
At 2021-12-3115,710,246shares

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2022-06-3028,890USD
At 2021-12-3174,181USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2022-06-3031,207USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2022-06-307,662,390USD
At 2021-12-318,056,638USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2022-06-307,696,815USD
At 2021-12-318,136,354USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2022-06-30307,412USD
At 2021-12-31279,265USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2022-06-301,896,633USD
At 2021-12-311,759,296USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2022-04-01 to 2022-06-30-5,164,368USD91
2022-01-01 to 2022-06-30-8,391,499USD181
2021-04-01 to 2021-06-30-3,294,212USD91
2021-01-01 to 2021-06-30-5,482,940USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2022-04-01 to 2022-06-302,034,456USD91
2022-01-01 to 2022-06-303,218,550USD181
2021-04-01 to 2021-06-301,329,213USD91
2021-01-01 to 2021-06-302,051,073USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2021-01-01 to 2021-06-30484USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2022-01-01 to 2022-06-30394,248USD181
2021-01-01 to 2021-06-30397,664USD181

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2021-01-01 to 2021-06-30-226,417USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2022-01-01 to 2022-06-30429,199USD181
2021-01-01 to 2021-06-30-32,816USD181

Inspect the source

Entity
Processa Pharmaceuticals, Inc. / CIK 0001533743
Captured
2026-09-20T09:16:31.348Z
SEC response SHA-256
5f3216d9024f2a7fc94b315f5bf243c7efb048273a6be394a2f74186d7af2a31

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001533743.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))